GLP-1 Receptor Agonists Show Disproportionate Alopecia Reporting in FDA Database Analysis
Alopecia Risk With GLP‐1 Receptor Agonists: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)
Abstract
Disproportionality analysis of FAERS data indicates a significant association between GLP-1 RAs and alopecia reporting, warranting further investigation.